Evaluation of the efficacy in exchanging Mitiglinide for Sitagliptin in good control type2 diabetic patients

Evaluation of the efficacy in exchanging Mitiglinide for Sitagliptin in good control type2 diabetic patients - Evaluation of the efficacy in exchanging Mitiglinide for Sitagliptin in good control type2 diabetic patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004670

Enrollment

Registered

2011-01-01

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type2 diabetic patients who has used mitiglinide and has kept HbA1c less than 6.5% for more than six month

Exclusion criteria

Exclusion criteria: Patients who refuse to change Mitiglinide to Sitagliptin, or patients who are inappropriate to use Sitagliptin

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Countries

Japan

Outcome results